Clinical trial · Interventional
Diagnostic Value of Bronchoscopic and Thoracoscopic Frozen Section Biopsies in Patients With Pleuropulmonary Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Lung cancer is the second most commonly diagnosed cancer worldwide, after breast cancer, and its incidence continues to grow. Flexible bronchoscopy is the diagnostic tool of choice to diagnose endobronchial malignancies. It allows inspection and biopsy of any endobronchial abnormalities under direct vision. Despite specimens are obtained under direct vision, there is a significant failure rate. This may necessitate repeating bronchoscopy. To guide the bronchoscopist on the quality and quantity of specimens during bronchoscopic biopsies for the diagnosis of lung cancer is rapid on-site evaluation (ROSE) of cytological specimens. Intra-procedural Frozen Section Evaluation (FROSE) of bronchoscopic biopsy specimens is an alternative to ROSE and helps preventing repeated bronchoscopies. Medical thoracoscopy increases the diagnostic yield of MPE as it offers the clinician a "window" for direct visualization and collection of samples from the parietal pleura.The acquracy of frozen section biopsies in pleural tumours is largely undefined. Confirmation of the pleural malignancy can lead to immediate pleurodesis following the pleural inspection and biopsy. To our knowledge limited studies discussed the value of frozen section in both bronchoscopic and thoracoscopic biopsies.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Event of Undetermined Intent (Y21-Y33) | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bronchoscopic and thoracoscopic frozen section biopsies | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Patients subjected for bronchoscopy or medical thoracoscopy
- description
- Bronchoscopic and thoracoscopic biopsies will be sent for both frozen section and permenant paraffin section
- interventionNames
- Diagnostic Test: Bronchoscopic and thoracoscopic frozen section biopsies
Primary outcomes (1)
- measure
- determining the spceficity and sensitivity of bronhcoscopic and thoracoscopic frozen section biopsy
- timeFrame
- 4 days
- description
- The accuracy of bronchoscopic and thoracoscopic frozen section to be malignant or non malignant or suspicious
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Patients presented with suspected lung neoplastic lesion indicated for bronchoscopy - * Patients presented with undiagnosed pleural effusion (suspected malignant pleural effusion) who are candidate for thoracoscopy Exclusion Criteria: * Age \<18 years old. * Contraindications for bronchoscopy: * Uncorrectable hypoxemia * Unstable angina * Uncontrolled arrhythmias * Unexplained or severe hypercarbia * Uncontrolled asthma * Uncorrectable coagulopathy * Contraindications for thoracoscopy: * Transudative pleural effusion
References
Publications (1)
- BACKGROUNDFielding D, Hopkins P, Serisier D. Frozen section of pleural biopsies at medical thoracoscopy assists in correctly identifying benign disease. Respirology. 2005 Nov;10(5):636-42. doi: 10.1111/j.1440-1843.2005.00761.x. PMID 16268918